Pediatric Pulmonary, Critical Care, and Allergy, Riley Hospital for Children, Indianapolis, IN, USA.
Pediatr Crit Care Med. 2013 Mar;14(3):306-9. doi: 10.1097/PCC.0b013e318271f48a.
A catheter thrombosis and the presence of a catheter-associated bloodstream infection (CBSI) often occur simultaneously, but it is unclear if or to what degree the two complications relate. Several animal and adult studies indicate a relationship between fibrin sheaths and thrombi in the development of CBSIs. To date, there has been limited human investigation in the pediatric population to determine a clear link between the presence of a thrombus and bacteremia. The use of alteplase for malfunctioning central venous catheter may indicate the formation of intraluminal thrombus or fibrin sheath. A catheter that requires alteplase is at higher risk of a CBSI.
A retrospective chart review from July 2008 to December 2010.
PICU.
All patients with central catheters admitted to the PICU.
No interventions performed with the retrospective study.
Number of total central venous catheters, number of central venous catheters that received treatment with alteplase, and number of CBSIs.
Preliminary data during the study period identified 3,289 central venous catheters. Twelve percent of these catheters required at least one dose of alteplase. There were 40 CBSIs during this same time period of which 28% received alteplase during the 5 days preceding the positive blood culture. The odds ratio for getting a CBSI when alteplase is administered is 2.87 (confidence interval 1.42-5.80; p = 0.002). The average age of the central venous catheters at time of infection was not statistically different, 16.1 days in the alteplase catheters compared with 25.6 days for the catheters that did not receive alteplase (p = 0.6).
There is a positive correlation between the use of alteplase for malfunctioning central venous catheters and the development of a CASBI. This is likely associated with the presence of an intraluminal fibrin sheath or thrombus. This study adds evidence linking thrombus formation to CBSI.
导管血栓和导管相关血流感染(CBSI)通常同时发生,但尚不清楚这两种并发症之间是否存在关联,以及关联程度如何。一些动物和成人研究表明,纤维蛋白鞘与 CBSI 中血栓的形成之间存在关系。迄今为止,在儿科人群中,关于血栓形成与菌血症之间的明确联系的研究有限。使用阿替普酶治疗功能失调的中心静脉导管可能表明管腔内血栓或纤维蛋白鞘的形成。需要阿替普酶的导管发生 CBSI 的风险更高。
2008 年 7 月至 2010 年 12 月的回顾性图表审查。
PICU。
所有入住 PICU 的中心导管患者。
回顾性研究未进行任何干预。
中心静脉导管总数、接受阿替普酶治疗的中心静脉导管数量和 CBSI 数量。
研究期间的初步数据确定了 3289 根中心静脉导管。其中 12%的导管至少需要一剂阿替普酶。在此期间发生了 40 例 CBSI,其中 28%在血培养阳性前的 5 天内接受了阿替普酶治疗。接受阿替普酶治疗时发生 CBSI 的优势比为 2.87(95%置信区间 1.42-5.80;p=0.002)。感染时中心静脉导管的平均年龄在统计学上没有差异,阿替普酶组为 16.1 天,未接受阿替普酶组为 25.6 天(p=0.6)。
对于功能失调的中心静脉导管,使用阿替普酶与 CASBI 的发生呈正相关。这可能与管腔内纤维蛋白鞘或血栓的存在有关。本研究提供了证据表明血栓形成与 CBSI 相关。